181 related articles for article (PubMed ID: 2329455)
21. Profile of neuroblastoma detected by mass screening, resected after observation without treatment: results of the Wait and See pilot study.
Oue T; Inoue M; Yoneda A; Kubota A; Okuyama H; Kawahara H; Nishikawa M; Nakayama M; Kawa K
J Pediatr Surg; 2005 Feb; 40(2):359-63. PubMed ID: 15750929
[TBL] [Abstract][Full Text] [Related]
22. Significance of chromosome 1p loss of heterozygosity in neuroblastoma.
Maris JM; White PS; Beltinger CP; Sulman EP; Castleberry RP; Shuster JJ; Look AT; Brodeur GM
Cancer Res; 1995 Oct; 55(20):4664-9. PubMed ID: 7553646
[TBL] [Abstract][Full Text] [Related]
23. One hundred neuroblastomas detected through a mass screening system in Japan.
Hachitanda Y; Ishimoto K; Hata J; Shimada H
Cancer; 1994 Dec; 74(12):3223-6. PubMed ID: 7982186
[TBL] [Abstract][Full Text] [Related]
24. Natural course of neuroblastoma detected by mass screening: s 5-year prospective study at a single institution.
Nishihira H; Toyoda Y; Tanaka Y; Ijiri R; Aida N; Takeuchi M; Ohnuma K; Kigasawa H; Kato K; Nishi T
J Clin Oncol; 2000 Aug; 18(16):3012-7. PubMed ID: 10944135
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical analysis of N-myc protein expression in neuroblastoma: correlation with prognosis of patients.
Hiyama E; Hiyama K; Yokoyama T; Ishii T
J Pediatr Surg; 1991 Jul; 26(7):838-43. PubMed ID: 1895195
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of genetic rearrangements in human neuroblastomas.
Brodeur GM
Clin Chem; 1989 Jul; 35(7 Suppl):B38-42. PubMed ID: 2568197
[TBL] [Abstract][Full Text] [Related]
27. The relationship between homovanillic/vanillylmandelic acid ratios and prognosis in neuroblastoma.
Nishi M; Miyake H; Takeda T; Hanai J; Fujita K; Ichimiya H; Tanaka T; Hirama T; Ishikawa Y; Kudoh T; Azuma H; Takase A
Oncol Rep; 1998; 5(3):631-3. PubMed ID: 9538165
[TBL] [Abstract][Full Text] [Related]
28. Disomy 1 with terminal 1p deletion is frequent in mass-screening-negative/late-presenting neuroblastomas in young children, but not in mass-screening-positive neuroblastomas in infants.
Kaneko Y; Kobayashi H; Maseki N; Nakagawara A; Sakurai M
Int J Cancer; 1999 Jan; 80(1):54-9. PubMed ID: 9935230
[TBL] [Abstract][Full Text] [Related]
29. Screening for neuroblastoma at 3 weeks of age: methods and preliminary results from the Quebec Neuroblastoma Screening Project.
Tuchman M; Lemieux B; Auray-Blais C; Robison LL; Giguere R; McCann MT; Woods WG
Pediatrics; 1990 Nov; 86(5):765-73. PubMed ID: 2152340
[TBL] [Abstract][Full Text] [Related]
30. Screening for neuroblastoma in North America. Preliminary results of a pathology review from the Quebec Project.
Takeuchi LA; Hachitanda Y; Woods WG; Tuchman M; Lemieux B; Brisson L; Bernstein M; Brossard J; Leclerc JM; Byrne TD
Cancer; 1995 Dec; 76(11):2363-71. PubMed ID: 8635044
[TBL] [Abstract][Full Text] [Related]
31. Competitive polymerase chain reaction for the determination of N-myc amplification in neuroblastoma: report of clinical cases.
Hasan Z; Inoue A; Ikeda H; Kamii Y; Obana K; Yokomori K; Tsuchida Y; Hemmi H; Shimatake H
Eur J Pediatr Surg; 1999 Jun; 9(3):138-41. PubMed ID: 10427487
[TBL] [Abstract][Full Text] [Related]
32. Stage IVS neuroblastoma: a clinical, histological, and biological analysis of 45 cases.
Hachitanda Y; Hata J
Hum Pathol; 1996 Nov; 27(11):1135-8. PubMed ID: 8912820
[TBL] [Abstract][Full Text] [Related]
33. [Tumor cytogenetics and prognosis in neuroblastoma].
Christiansen H; Lampert F
Monatsschr Kinderheilkd; 1989 Oct; 137(10):666-71. PubMed ID: 2586532
[TBL] [Abstract][Full Text] [Related]
34. A population-based study of the usefulness of screening for neuroblastoma.
Woods WG; Tuchman M; Robison LL; Bernstein M; Leclerc JM; Brisson LC; Brossard J; Hill G; Shuster J; Luepker R; Byrne T; Weitzman S; Bunin G; Lemieux B
Lancet; 1996 Dec 21-28; 348(9043):1682-7. PubMed ID: 8973429
[TBL] [Abstract][Full Text] [Related]
35. A 5-year (1990-1994) neuroblastoma screening feasibility study in France. Methodology and preliminary observations.
Mathieu P; Frappaz D; Chauvin F; Combaret V; Vercherat M; Brunat-Mentigny M; David L; Esteve J; Favrot M; Fouillat V; Greffe J; Lasset C; Renaud P; Philip T
Early Hum Dev; 1996 Sep; 46(1-2):177-96. PubMed ID: 9019414
[TBL] [Abstract][Full Text] [Related]
36. Mass screening for neuroblastoma in Japan.
Sawada T; Sugimoto T; Kawakatsu H; Matsumura T; Matsuda Y
Pediatr Hematol Oncol; 1991; 8(2):93-109. PubMed ID: 1863547
[TBL] [Abstract][Full Text] [Related]
37. Amplification of N-myc gene and increase of urinary VMA and HVA in patients with neuroblastic tumors.
Akimaru K; Shoji T; Fukunaga Y; Yamamoto M; Ishizaki R; Nomura N
Nihon Ika Daigaku Zasshi; 1994 Apr; 61(2):148-53. PubMed ID: 8195324
[TBL] [Abstract][Full Text] [Related]
38. Screening for neuroblastoma in the north of England.
Parker L; Craft AW; Dale G; Bell S; Cole M; McGill AC; Seviour JA; Smith J
BMJ; 1992 Nov; 305(6864):1260-3. PubMed ID: 1303649
[TBL] [Abstract][Full Text] [Related]
39. Chromosome 10 abnormality predicts prognosis of neuroblastoma patients with bone marrow metastasis.
Jiang CY; Xu X; Jian BL; Zhang X; Yue ZX; Guo W; Ma XL
Ital J Pediatr; 2021 Jun; 47(1):134. PubMed ID: 34108028
[TBL] [Abstract][Full Text] [Related]
40. Thin-layer chromatography of urinary homovanillic acid and vanillylmandelic acid for large-scale neuroblastoma mass screening.
Auray-Blais C; Giguère R; Lemieux B
Med Pediatr Oncol; 1989; 17(5):364-7. PubMed ID: 2796851
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
